Inhibrx Biosciences (NASDAQ:INBX – Free Report) had its target price cut by HC Wainwright from $245.00 to $220.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibrx Biosciences’ Q4 2026 earnings at ($2.27) EPS, FY2026 earnings at ($9.22) EPS, Q1 2027 earnings at ($2.23) EPS, Q2 2027 earnings at ($2.18) EPS, Q3 2027 earnings at ($1.94) EPS, Q4 2027 earnings at ($1.72) EPS and FY2027 earnings at ($8.02) EPS.
A number of other research firms also recently commented on INBX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibrx Biosciences in a research report on Friday, September 11th. Wall Street Zen cut shares of Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. Finally, Citigroup reissued a “market perform” rating on shares of Inhibrx Biosciences in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inhibrx Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $185.00.
Read Our Latest Analysis on INBX
Inhibrx Biosciences Stock Down 6.9%
Shares of INBX opened at $69.06 on Monday. The stock has a 50 day moving average price of $92.72 and a 200 day moving average price of $92.13. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -7.62 and a beta of 4.03. Inhibrx Biosciences has a 52-week low of $57.30 and a 52-week high of $155.29.
Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($2.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.45) by ($0.01). The business had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.90 million. On average, equities analysts anticipate that Inhibrx Biosciences will post -9.70 EPS for the current fiscal year.
Insider Transactions at Inhibrx Biosciences
In other news, Director Douglas Forsyth purchased 2,500 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were bought at an average price of $114.65 per share, with a total value of $286,625.00. Following the completion of the transaction, the director directly owned 227,064 shares in the company, valued at approximately $26,032,887.60. This represents a 1.11% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kimberly Manhard sold 500 shares of Inhibrx Biosciences stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $110.26, for a total value of $55,130.00. Following the transaction, the director directly owned 8,000 shares in the company, valued at approximately $882,080. This trade represents a 5.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have bought 62,540 shares of company stock worth $6,347,507 and have sold 1,500 shares worth $168,590. 18.26% of the stock is owned by insiders.
Hedge Funds Weigh In On Inhibrx Biosciences
A number of hedge funds have recently modified their holdings of INBX. HighTower Advisors LLC increased its holdings in shares of Inhibrx Biosciences by 1.6% in the 3rd quarter. HighTower Advisors LLC now owns 884,441 shares of the company’s stock valued at $88,515,000 after acquiring an additional 13,890 shares during the period. Bank of America Corp DE acquired a new stake in Inhibrx Biosciences during the 2nd quarter worth $79,698,000. BlackRock Inc. acquired a new stake in Inhibrx Biosciences during the 2nd quarter worth $78,261,000. Parkman Healthcare Partners LLC purchased a new position in Inhibrx Biosciences during the 2nd quarter worth $24,346,000. Finally, Soleus Capital Management L.P. purchased a new position in Inhibrx Biosciences during the 3rd quarter worth $21,017,000. 82.46% of the stock is currently owned by hedge funds and other institutional investors.
Top Inhibrx Biosciences Stories
Here are a few of the latest stories about INBX:
- Positive Sentiment: Inhibrx reported that ozekibart combined with irinotecan and temozolomide produced a 62.7% overall response rate and an 86.3% disease control rate in a Phase 1/2 study of relapsed or refractory Ewing sarcoma. The company also described responses as durable in heavily pretreated patients. Inhibrx Announces Updated Clinical Data for Ozekibart in Ewing Sarcoma
- Neutral Sentiment: HC Wainwright maintained its Buy rating and a $220 price target, while adjusting earnings estimates in both directions: it raised several 2027 forecasts but lowered its FY2026 estimate to a larger expected loss of $9.22 per share. Inhibrx Biosciences analyst estimates
- Negative Sentiment: A separate report says HC Wainwright cut its price target, tempering the otherwise supportive Buy rating; the available report cites a $220 target. Inhibrx Biosciences Stock Price Target Cut by HC Wainwright
About Inhibrx Biosciences
Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.
Further Reading
- Five stocks we like better than Inhibrx Biosciences
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
